The FDA has mandated updated safety labeling for two respiratory syncytial virus vaccines, Pfizer's Abrysvo and GlaxoSmithKline's Arexvy, following the identification of an increased risk of ...
Ramos, previously Pfizer's senior vice president and global head of BioTherapeutics R&D, has been appointed to the board of ...
As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...
On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of ...
Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...
Zacks.com on MSN1h
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded DealThis week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...
Tens of millions of pounds in investment is being provided by the group of firms which includes AstraZenecaa and Pfizer ...
3hon MSN
Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...
A world leading UK Biobank study of half a million Brits could unlock the mysteries of ‘proteomics’ to prevent and cure ...
Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback